Apr 19 |
NLS Pharmaceutics receives Nasdaq staff delisting determination
|
Apr 19 |
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
|
Mar 22 |
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
|
Mar 20 |
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
|
Mar 20 |
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
|
Mar 14 |
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
|
Mar 11 |
Nasdaq accepts NLS Pharmaceutics’ plan to regain listing compliance
|
Mar 11 |
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
|
Feb 23 |
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
|
Jan 12 |
NLS Pharmaceutics receives non-compliance letter from Nasdaq
|